FIELD: biochemistry.
SUBSTANCE: present invention relates to novel pyrazolo [4,3-h]quinazoline compounds selected from the group indicated below and corresponding to general formula (I). Cell proliferative disorders is selected from the group consisting of benign prostate hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis. Inflammatory and autoimmune diseases are selected from multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases (IBD), Crohn's disease, irritable bowel syndrome, pancreatitis, ulcerative colitis, diverticulosis, myasthenia gravis, vasculitis, psoriasis, scleroderma, asthma, allergy, systemic sclerosis, vitiligo, arthritis such as osteoarthritis, juvenile rheumatoid arthritis, ankylosing spondylitis. Formula (I)
where radicals A, R1-R3, R5 correspond to the values, said compounds, which are selected from 1-(2-hydroxyethyl)-8-(methylsulfanyl)-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-(2-hydroxyethyl)-8-methoxy-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-tert-butyl-N-methyl-8-(methylsulfanyl)-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-tert-butyl-N-[2-(dimethylamino)etliyl]-8-(metliylsulfanyl)-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-tert-butyl-N-(2-hydroxyethyl)-8-(methylsulfanyl)-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-tert-butyl-N-(1-methylpiperidin-4-yl)-8-(methylsulfanyl)-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-tert-butyl-N-[2-(1H-imidazol-5-yl)ethyl]-8-(methylsulfanyl)-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-[2-(dimethylamino)ethyl]-8-(methylsulfanyl)-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 6-amino-1-[2-(dimethylamino)ethyl]-8-(metliylsulfanyl)-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 2-[2-(dimethylamino)ethyl]-8-(methylsulfanyl)-2H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-(2-aminoethyl)-8-(methylsulfanyl)-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 2-(2-aminoethyl)-8-(methylsulfanyl)-2H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-(methylsulfanyl)-1-(piperidin-4-ylmethyl)-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-(methylsulfanyl)-2-(piperidin-4-ylmethyl)-2H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-methyl-8-[4-(piperazin-1-yl)phenoxy]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-methyl-8-phenoxy-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-(3-aminophenoxy)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-(4-aminophenoxy)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-methyl-8-(pyridin-4-yloxy)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-(2-fluoroethoxy)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-methyl-8-[4-(4-methylpiperazin-1-yl)phenoxy]-4,5H-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-methyl-8-[4-(4-methylpiperazin-1-yl)phenoxy]-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-methyl-8-[4-(piperazin-1-yl)phenoxy]-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-[2-bromo-4-(4-methylpiperazin-1-yl)phenoxy]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-[2-bromo-4-(4-methylpiperazin-1-yl)phenoxy]-1-methyl-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-methyl-8-[3-(piperazin-1-yl)phenoxy]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-methyl-8-[3-(piperazin-1-yl)phenoxy]-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-[3-(dimethylamino)phenoxy]-1-methyl-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-(2-chlorophenoxy)-1-methyl-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-(2-fluorophenoxy)-1-methyl-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-[2-fluoro-4-(4-methylpiperazin-1-yl)phenoxy]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-[2-fluoro-4-(4-methylpiperazin-1-yl)phenoxy]-1-methyl-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-[2-acetyl-4-(4-methylpiperazin-1-yl)phenoxy]-1-methyl-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-[2-acetyl-4-(piperazin-1-yl)phenoxy]-1-methyl-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-[2-cyano-4-(4-methylpiperazin-1-yl)phenoxy]-1-methyl-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-(2-hydroxyethyl)-8-phenoxy-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-(2-hydroxyethyl)-8-[4-(4-methylpiperazin-1-yl)phenoxy]-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-(2-hydroxyethyl)-8-[3-(4-methylpiperazin-1-yl)phenoxy]-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-(2-hydroxyethyl)-8-(3-nitrophenoxy)-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-methyl-8-(3-nitrophenoxy)-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-methyl-8-[3-(4-methylpiperazin-1-yl)phenoxy]-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-tert-butyl-8-[4-(4-methylpiperazin-1-yl)phenoxy]-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-methoxy-1-methyl-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-ethoxy-1-methyl-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-methoxy-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-(3-formylphenoxy)-1-methyl-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-methyl-8-{3-[(4-methylpiperazin-1-yl)methyl]phenoxy}-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-[3-(hydroxymethyl)phenoxy]-1-methyl-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-{3-[(dimethylamino)methyl]phenoxy}-1-methyl-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-methyl-8-[3-(morpholin-4-ylmethyl)phenoxy]-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-(3-aminophenoxy)-1-methyl-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-(3-aminophenoxy)-1-(2-hydroxyethyl)-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 8-(methylsulfanyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-(2-fluoroethyl)-8-(methylsulfanyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-(2-chloroethyl)-8-(methylsulfanyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-(2-hydroxyethyl)-8-(methylsulfanyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-(2-methoxyethyl)-8-(methylsulfanyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-[3-(dimethylamino)propyl]-8-(methylsulfanyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, 1-(1-amino-2-methyl-1-oxopropan-2-yl)-8-(methylsulfanyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, and other compounds specified in claim 1.
EFFECT: compounds have dysregulated protein kinase PIM-1, PIM-2, PIM-3 activity and can be used for treating diseases caused by and/or associated with said disorder, such as cancer, cell proliferative disorders and diseases and immune cell-associated diseases and disorders.
15 cl, 2 dwg, 53 ex, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
TRICYCLIC PYRROLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND USE THEREOF AS KINASE INHIBITORS | 2012 |
|
RU2591191C2 |
AVB6 INTEGRIN INHIBITORS | 2018 |
|
RU2769702C2 |
PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2001 |
|
RU2340611C2 |
COMPOUNDS WITH CONDENSED RINGS | 2019 |
|
RU2783414C2 |
BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
PYRIMIDINE COMPOUND WITH CONDENSED RINGS, ITS INTERMEDIATE COMPOUND, METHOD OF PRODUCING, COMPOSITION AND USE | 2016 |
|
RU2732576C2 |
SELECTIVE KINASE JAK1 INHIBITOR | 2020 |
|
RU2818002C2 |
PIPERIDINE UREA DERIVATIVES | 2014 |
|
RU2666894C2 |
TRIAZOLO-PYRIMIDINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2802866C2 |
COMPOSITION OF TETRAHYDROQUINOLINES AS BROMODOMAIN BET MODIFYING AGENTS | 2014 |
|
RU2727169C2 |
Authors
Dates
2018-04-28—Published
2011-12-16—Filed